Regional Marketing Director, Oncology

Remote

Apply with AI Apply

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, OncologyIndustries

Requirements

Candidates should possess a Bachelor's degree and have demonstrated experience in marketing, preferably within the pharmaceutical or biotechnology industry. Strong leadership skills and a deep understanding of the oncology landscape are essential.

Responsibilities

The Regional Marketing Director will develop and lead a thought leader engagement plan within the gynecologic oncology community, identify and develop innovative marketing tactics, recruit and engage speakers, collaborate on a Peer-to-Peer platform, drive compliance efforts, lead an annual insights plan, participate in brand strategy development, establish relationships with SGOs and key organizations, foster cross-functional alignment, and partner with commercial teams to achieve brand and business objectives.

Skills

Thought Leader Engagement

KOL Relationship Management

Speaker Bureau Management

Regulatory Compliance

Market Strategy

Oncology Knowledge

Gynecologic Oncology

Peer-to-Peer Platform Development

Congress Planning

Cross-functional Collaboration

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free